Filtered By:
Cancer: Carcinoma
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1249 results found since Jan 2013.
Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments
This study reviewed the recent trends in the epidemiological characteristics of HBV in the Gambia. The researchers conducted an online literature search for primary studies on HBV prevalence published in the past two decades from Jan 1992 to Feb 2022 inclusive on Google Scholar, PubMed, and Scopus. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness, and methodological coherence. We found that HBV infection prevalence is above 8% in The Gambia. Moreover, HBV is the most common cause of hepatocellular carcinoma (HCC) in Gambia. Liver cirrhosis and HCC hav...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Muhammed Camara Marcarious M Tantuoyir SeyedAhmad SeyedAlinaghi Fereshteh Ghiasvand Zahra Ahmadinejad Source Type: research
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents.PMID:37694781 | DOI:10.2174/1389557523666230911141339
Source: Mini Reviews in Medicinal Chemistry - September 11, 2023 Category: Chemistry Authors: Manish Chaudhary Shubham Kumar Paranjeet Kaur Sanjeev Kumar Sahu Amit Mittal Source Type: research
Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
This study offers a prospective strategy to develop personalized neoantigen vaccines for augmenting cancer immunotherapy efficiency in immune "cold" HCC.PMID:37552209 | DOI:10.15252/emmm.202216836
Source: Molecular Medicine - August 8, 2023 Category: Molecular Biology Authors: Ming Wu Zijin Luo Zhixiong Cai Qianqian Mao Zhenli Li Hao Li Cao Zhang Yuting Zhang Aoxue Zhong Liming Wu Xiaolong Liu Source Type: research
Analysis of hepatocellular carcinoma associated with hepatitis B virus
J Cell Mol Med. 2023 Jul 30. doi: 10.1111/jcmm.17867. Online ahead of print.ABSTRACTThe hepatitis B virus (HBV) is considered one of the main driving forces in the development of hepatocellular carcinoma (HCC). Human HBV is a partially double-stranded DNA (dsDNA) virus consisting of approximately 3.2 kbp. HBV predominantly infects hepatocytes via the receptor sodium taurocholate cotransporting polypeptide (NTCP) and coreceptor hepatic proteoglycan. The replication of HBV in hepatocytes leads to apoptosis while simultaneously leading to cirrhosis and cancer. Although the integration of dsDNA into the hepatocyte genome seems...
Source: J Cell Mol Med - July 30, 2023 Category: Molecular Biology Authors: Litao Zheng Source Type: research
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
In this study, we demonstrate, for the first time, that treating established syngeneic murine colon and breast carcinoma tumors with a CSF1R-blocking antibody also promotes the expansion of neoepitope-specific T cells. To assess the role of tumor-derived CSF1 in these model systems, we generated and characterized CSF1 CRISPR-Cas9 knockouts. Eliminating tumor-derived CSF1 results in decreased tumor growth and enhanced immunity against tumor-associated neoepitopes, potentially promoting an immune permissive tumor microenvironment in tumor-bearing mice. The combination of neoepitope vaccine with anti-PDL1 in the MC38 CSF1-/- ...
Source: Cancer Control - July 28, 2023 Category: Cancer & Oncology Authors: Maria Del Mar Maldonado Jeffrey Schlom Duane H Hamilton Source Type: research
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis
MedComm (2020). 2023 Jul 18;4(4):e286. doi: 10.1002/mco2.286. eCollection 2023 Aug.ABSTRACTTumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines could promote a clinical benefit to advanced cancer patients is highly unknown. PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023. Random effects models were employed. Clinical benefit (objective response rate [ORR], disease control rate [DCR], 1-year/2-year progression-free survival [PFS], and overall survival [OS]) and safety (vaccine-related grade 3-5 adverse events [AEs]) were evaluated. Overall, 984 patients (32 trials) were e...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Tian-Yi Zhang Hang Xu Xiao-Nan Zheng Xing-Yu Xiong Shi-Yu Zhang Xian-Yanling Yi Jin Li Qiang Wei Jian-Zhong Ai Source Type: research
Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome
Biomed Pharmacother. 2023 Jun 30;165:115104. doi: 10.1016/j.biopha.2023.115104. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly improved the prognosis of HCC; however, the therapeutic response remains unsatisfactory in a substantial proportion of patients or needs to be further improved in responders. Herein, other methods of immunotherapy, including vaccine-based immunotherapy, adoptive cell therapy, cytokine delivery, kynurenine pathway inhibition, and gene delivery, h...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 2, 2023 Category: Drugs & Pharmacology Authors: Fatemeh Afra Amir Ali Mahboobipour Amir Salehi Farid Moein Ala Source Type: research
Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research
